Intra-Cellular, Takeda terminate collaboration to develop PDE1 inhibitors for CNS disorders
Under the terms of the agreement, Intra-Cellular Therapies has regained all worldwide development and commercialization rights for the compounds previously licensed to Takeda. Takeda will be responsible for